First Tracks Biotherapeutics UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Good morning, everyone. Thank you so much for joining us on our next session. I'm Michael Yee, Global Head of Biotech Research at UBS, and I'm very excited to have the team from First Tracks Biotherapeutics here with us at the conference, specifically President and Chief Executive Officer Dan Faga up here with us. Dan- Hi, Steve. Mike. Thank you for joining us.
It's a pleasure to have you at our conference.
Thank you very much. Nice to be here.
Thank you. Well, let's start with the fact that First Tracks has been putting up some great data with your lead program, a CD122 antagonist antibody, for many autoimmune diseases, but specifically in celiac disease. If I could have you just briefly introduce the company to the audience. Here we are in London, so broadening out the investor base. I would love for you to explain to everybody what ANB033 is and what makes it unique.
Thank you very much. Nice to see everyone here today. Representing First Tracks Bio. Yeah First Tracks goes by First Tracks.
We have three clinical stage I&I programs within the company, as well as a research platform. We're a new company. We spun out from our predecessor about six, eight months ago. To your point, with our lead program, ANB033, this is a CD122 antagonist for celiac disease and EoE, amongst other targets or indications that we'll be talking about. We did recently announce top line results from our first of two ongoing celiac trials. So really exciting results. First time in the treatments in this disease where there is no approved therapeutics, where we saw an impact both on mucosal injury of celiac disease as well as on symptoms. It's an exciting start to the story here at First Tracks. We have a number of catalysts already lined up for next year across all three of our programs.
Before we get into all three of the programs, let's focus on at least the lead program, of course, which had data recently. There's been a lot of focus on this class because 2026 was the year that three companies, at least, have put up various degrees of phase I data in celiac disease, and all the three molecules are at least somewhat similar in terms of mechanism. Can you explain how you think about the three different programs and how you think about your program as differentiated from the others? Do you think it's better than theirs? Do you think it is more potent? How do you think about that? Argenx just acquired Forte, paid about $2 billion.
$2 billion, and put up some good data in phase I. Teva put up some good data as well, and their stock traded up. In fact, they just had an R&D Day and spent a lot of time talking about this. Tell us about yours, and is your program differentiated and perhaps superior?
As these things go, there is a lot of competitive data right now in the space.
Yeah. I think when you step back and you look across these three different programs you just cited, we've all had positive data in celiac disease.
What I said in my opening remarks, there's nothing approved in celiac disease today. I think we're onto something right now in terms of actually targeting the biology of this disease for the first time directly. Historical approaches generally focused or centered on the targeting of gluten, the antigen Yeah in celiac disease.
Yeah. What we do with a CD122 antagonist is we are binding two different T cells that are lit up in this inflammatory cycle.
We specifically block the signaling of both IL-15 and IL-2. This is a dual mechanism antagonist.
Okay. One of our competitors, argenx, has a similar targeted drug.
Okay. Teva is only targeting one of those two cytokines.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
